Endoglin-targeted cancer therapy. - Wikidata - awgldk - TriplyDB

Endoglin-targeted cancer therapy.

Endoglin-targeted cancer therapy.

http://www.wikidata.org/entity/Q37804900

about

Role of endoglin in fibrosis and scleroderma Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging Surface engineering of graphene-based nanomaterials for biomedical applications Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA Multimodality molecular imaging of CD105 (Endoglin) expression.Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials.Stem cell pathways contribute to clinical chemoresistance in ovarian cancer Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles.Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.Angiogenesis and lymphangiogenesis in the spectrum of leprosy and its reactional forms.Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload.Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting.Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study.In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers.Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW.Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment Tumor vasculature targeting and imaging in living mice with reduced graphene oxide.Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination Molecular imaging of retinal disease.PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence Lymphatic Contribution to the Cellular Niche in Heterotopic Ossification Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles.In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.

P2860

Q26821836-9BC6F198-93F8-46C3-83A0-2E18A5AAECEA Q26827998-273186E6-076D-4A55-805B-2A23881F4FD6 Q26853158-E4089E99-6C3D-415C-9F27-CCAF0B794AEA Q28078154-77FC78F0-BE6C-44C5-9A7F-C2A82322F23F Q28741667-BD1C375A-7EDF-4451-8235-8BEFA0B869F7 Q30476445-BA819283-2FF3-4632-9215-80941E14A613 Q33687218-A61F5E94-148F-4F95-BF25-F7AB128E26BA Q34019838-D92053C2-616C-40D3-B315-BBA95F37C154 Q34092005-C4FB7F01-38B6-4D66-86BE-BDE8CDFF4233 Q34178035-73438180-453A-4326-B015-F3D7FAAAF0BC Q34446399-209978CD-2F44-4962-A5F1-F592AA014512 Q34540047-570D8C82-9C0A-43C0-9104-4A543A804B6E Q34990214-80F4CC9D-3F13-416D-A759-1F9EA32E7DC5 Q35026300-E0077281-B2C0-4686-B2C8-90D062B84183 Q35079462-0CC23DB0-A3F8-4FA7-9B80-09F8B1CCB396 Q35158941-8ED21425-FC06-47C2-98E6-8BE3F12CCBC2 Q35291271-7B8588E7-E746-4F71-B59A-22792ED4FDC9 Q35536671-E6EAE92E-A7CD-400F-AC3D-75B2776E7346 Q35554806-809E2229-1B9B-4C19-9A09-50364D4C97C9 Q35587248-EEB14C95-B126-4292-A043-C242989F7789 Q35809541-A81F1FBE-A150-4D88-AF14-587CDB2CDBFB Q35851032-7827F0EF-9267-46A5-AE0C-C50B1CC742A5 Q35854802-06DC07BA-006A-4EA8-A661-69DF015904ED Q35856996-AE83EFA0-BC8B-46E0-A9C3-6100861D34FC Q36034526-BD00851D-111F-4E11-97AF-D67A184EB050 Q36061812-45A14E45-BF57-4A88-9D8D-CCDE7A89C624 Q36185354-B6E68EB8-0EBD-4637-8EB0-64B0E9716E86 Q36205086-23EE7A46-9E75-42E4-8091-06F8D6877CFC Q36285676-42F5EA93-E359-4C66-90B7-F8C0A5F85CD4 Q36406701-1DDBA50E-CE53-46A8-AEEF-668F868E13C9 Q36586091-6AFA5C4B-6A18-4C85-9664-E9DF5B4DE7C0 Q36604948-30E4F0A1-7BD2-4A5E-9516-61A6332B31B9 Q36694132-9E1BEB6C-0EA4-4666-9283-3D373EF63C8D Q36696874-80D04633-5DC8-48CA-AA0E-3FD21860B1DC Q36763112-4492F4DA-3F0D-4F71-941F-E664573B1DD2 Q36996613-1488E5D3-1696-420B-86A4-AA894A667E7A Q37099146-68623A3A-62C0-49FD-A567-6C0575BA3B71 Q37202881-B547126A-A6EC-4AC8-81B7-88756A64EDFC Q37327759-06995809-59BF-4CEB-B5AD-A2B097FF4603 Q37520379-3B1638CF-42A9-46C9-8AB9-CA979E1252DE

P2860

Endoglin-targeted cancer therapy.

http://www.wikidata.org/entity/Q37804900

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Endoglin-targeted cancer therapy.

@en

Endoglin-targeted cancer therapy.

@nl

type

label

Endoglin-targeted cancer therapy.

@en

Endoglin-targeted cancer therapy.

@nl

prefLabel

Endoglin-targeted cancer therapy.

@en

Endoglin-targeted cancer therapy.

@nl

P1433

Q37804900-E563F5B4-B086-4285-845E-3563D337AE5A

P1476

Q37804900-ACB44B75-07EE-479D-A558-235C7FC05699

P2093

Q37804900-195670AF-1A3D-4553-AD75-D281810646B3

Q37804900-36CDDB4E-88B8-478D-840C-BDB00CF9F9F3

Q37804900-3B63D365-BEEF-4286-953A-E03056DC632F

Q37804900-40C6011F-E3FD-42FB-8DB8-66D9B9C00A51

Q37804900-6B425FFF-2222-480F-9C78-CD8436717ACE

Q37804900-A03DE950-DEF6-4AB5-975F-77E214C5C222

Q37804900-BB052373-A417-4BF7-9489-FCF2F1CA3A44

Q37804900-BCA2011C-7B40-482F-949D-670D065160A4

Q37804900-E0730203-681B-478B-83BC-CA0816290EF7

Q37804900-F0B72CE1-35BF-4C69-85F2-8691CA2329E1

P2860

Q37804900-0217E51B-D437-4EF4-9D3A-683645F3C81F

Q37804900-0B58D7FC-956E-4D70-A6E7-EA2E2CBCC9DE

Q37804900-0BC68859-8B2E-4892-AD86-E2C1076C1031

Q37804900-182574E7-23F3-4E47-8CC2-FC510D5F3774

Q37804900-19971CCE-5E7B-4313-8E3B-2A7FB45031E9

Q37804900-1FA7FA60-9DA1-4ACC-9511-903A46BE5814

Q37804900-1FD9035B-6D25-445C-8566-463FDF9B73B4

Q37804900-31FB150B-1A10-4911-902F-D4AD032A2ACE

Q37804900-3213EA3B-511D-4044-9848-9A440CD2B1D4

Q37804900-3507E8E0-761C-4E10-B4FF-3FCFD09D469C

P304

Q37804900-5B907177-3441-4F45-BDB0-5A795F854DC5

P31

Q37804900-5359751E-13D6-486C-8ADB-625953442D60

P433

Q37804900-6222D37D-88F9-4669-802C-6F7F16423BFB

P478

Q37804900-8B2C07E8-42A5-4DB0-A029-504ABD901A9E

P577

Q37804900-DC3691B7-06EC-4D6D-957A-74E1810AEDC8

P698

Q37804900-09439149-28FF-4DD7-80A6-D26E0B86D516

P932

Q37804900-D03792BC-AE6E-4DD7-890D-24AE89495C8C

P1433

Current Drug Delivery

P1476

Endoglin-targeted cancer therapy.

@en

P2093

Akinao Haba

http://www.w3.org/2001/XMLSchema#string

Ben K Seon

http://www.w3.org/2001/XMLSchema#string

Fumihiko Matsuno

http://www.w3.org/2001/XMLSchema#string

Hilda Tsai

http://www.w3.org/2001/XMLSchema#string

Hirofumi Toi

http://www.w3.org/2001/XMLSchema#string

Masanori Tsujie

http://www.w3.org/2001/XMLSchema#string

Naoko Harada

http://www.w3.org/2001/XMLSchema#string

Norihiko Takahashi

http://www.w3.org/2001/XMLSchema#string

Shima Uneda

http://www.w3.org/2001/XMLSchema#string

Tomoko Tsujie

http://www.w3.org/2001/XMLSchema#string

P2860

TGF-beta signal transduction

Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II

Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen

Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions

Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta

Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Defective angiogenesis in mice lacking endoglin

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells

P304

135-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21034418

http://www.w3.org/2001/XMLSchema#string

P932

4353483

http://www.w3.org/2001/XMLSchema#string